RELCOVAPTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H27Cl2N3O7S
Molecular Weight	620.501
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1OC)S(=O)(=O)N2[C@@H](C(=O)N3CCC[C@H]3C(N)=O)[C@](O)(C4=CC(Cl)=CC=C24)C5=CC=CC=C5Cl

InChI

InChIKey=CEBYCSRFKCEUSW-NAYZPBBASA-N

InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C28H27Cl2N3O7S
Molecular Weight	620.501
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12436936
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15823830 | https://www.ncbi.nlm.nih.gov/pubmed/14678081 | https://www.ncbi.nlm.nih.gov/pubmed/11035135

Relcovaptan is a potent, orally active nonpeptide vasopressin V1a antagonist that was undergoing clinical development with Sanofi-Synthélabo (formerly Sanofi) in France. SR49059 is specifically and selectively antagonizes the effect of vasopressin on the V1a receptor in animals’ and in humans. The drug has been shown to have an excellent safety profile in single and repeated dose toxicological studies in animals. In the human uterus in vitro, SR49059 caused a dose-dependent inhibition of vasopressin V1a receptor-mediated activity of myometrial strips and isolated uterine arteries. In vivo in nonpregnant women, an inhibition of vasopressin-induced uterine activity has been observed.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vasopressin V1a receptor 18 Target ID: CHEMBL1889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21885275	Antagonist 2849		13.0 nM [IC50]
Vasopressin V2 receptor 16 Target ID: CHEMBL1790 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12036368	Antagonist 2849		178.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Preterm labor 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14678081	Primary	Not Provided 511	Unknown Approved Use Unknown
Raynaud's disease 5 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11035135	Primary	Not Provided 511	Unknown Approved Use Unknown
Dysmenorrhea 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10826575	Primary	Not Provided 511	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
cAMP/PKA-dependent increases in Ca Sparks, oscillations and SR Ca stores in retinal arteriolar myocytes after exposure to vasopressin.	2010-03	19959643
[Vasopressin receptor antagonists and heart failure].	2009-11	19885790
Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.	2008-08	18467593
Non-peptide arginine-vasopressin antagonists: the vaptans.	2008-05-10	18468546
The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat.	2008	19388361
Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema.	2008	19388360
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.	2007-01	16926443
Vasopressin antagonists.	2006-08	16794787
Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor.	2006-05-26	16565083
Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.	2006-05-24	16678155
Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.	2006-04	16553642
Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies.	2006-04	16449345
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.	2006-01	16319185
Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat.	2006	16671476
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.	2005-11	16158071
Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-.	2005-04	15685210
The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.	2005-02	15823830
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.	2005-01	15722249
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.	2004-08	15166253
Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage.	2004-04	15053824
Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.	2004-01	14678081
Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors.	2003-10-10	12869559
Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.	2003-09	12736162
Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication.	2003-06	12857435
Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent.	2003-02	14565536
Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model.	2002-12	12468809
Interplay between presynaptic and postsynaptic activities is required for dendritic plasticity and synaptogenesis in the supraoptic nucleus.	2002-01-01	11756510
Placental transfer of SR49059 in the human dually perfused cotyledon in vitro.	2001-11	11718575
Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift.	2001-07-06	11448485
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.	2001-07	11429400
A nonpeptide vasopressin V(1a) receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets.	2001-06	11468030
High concentrations of oxytocin cause vasoconstriction by activating vasopressin V1A receptors in the isolated perfused rat kidney.	2001-04	11330329
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.	2000-10	11012895
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.	2000-07	10866830
Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats.	2000-03	10731046
Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition.	2000-02	10679504
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.	1999-10	10519430
Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.	1999-07-02	10440088
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.	1998-12	9884074
Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.	1997-10-17	9334232
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.	1997-10	9322919
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes.	1994-02-28	8123034
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.	1994-02-04	8106369

Patents

Sample Use Guides

In Vivo Use Guide

25, 75 or 200 mg

Route of Administration: Oral

In Vitro Use Guide

MDCK II cells were seeded on 12 multiwell filters (Costar) at a density of 150,000 cells/cm2 and grown for 3 days. Cells were subsequently treated with the antagonists for 16 h, followed by three washes with ice-cold phosphate-buffered saline containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS-CM). The cells were then incubated for 1 h on ice with [3H]AVP (PerkinElmer Life Sciences, Boston, MA) and the antagonist (Relcovaptan) diluted in PBS-CM. Cells were washed three times with ice-cold PBS-CM, followed by excision of the filters and counting of the radioactivity

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:25:57 GMT 2025` Edited by `admin` on `Wed Apr 02 08:25:57 GMT 2025`
Record UNII	C1GL8G6G0O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SR-49059

Preferred Name

English

RELCOVAPTAN

Official Name

English

relcovaptan [INN]

Common Name

English

2-PYRROLIDINECARBOXAMIDE, 1-(((2R,3S)-5-CHLORO-3-(2-CHLOROPHENYL)-1-((3,4-DIMETHOXYPHENYL)SULFONYL)-2,3-DIHYDRO-3-HYDROXY-1H-INDOL-2-YL)CARBONYL)-, (2S)-

Common Name

English

(2S)-1-(((2R,3S)-5-CHLORO-3-(O-CHLOROPHENYL)-1-((3,4-DIMETHOXYPHENYL)SULFONYL)-3-HYDROXY-2-INDOLINYL)CARBONYL)-2-PYRROLIDINECARBOXAMIDE

Common Name

English

Relcovaptan [WHO-DD]

Common Name

English

SR49059

Code

English

TDI-0134

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C2180